Improving tuberculosis diagnostics with biomarkers

References

• World Health Organization. Global Tuberculosis Report 2014. Geneva, Switzerland: World Health Organization; 2014.
   Google Scholar
• Wang JY, Hsueh PR, Jan IS, et al. Empirical treatment with a fluoroquinolone delays the treatment for tuberculosis and is associated with a poor prognosis in endemic areas. Thorax. 2006;61:903–908.
   PubMed Web of Science ®Google Scholar
• Behr MA, Warren SA, Salamon H, et al. Transmission of Mycobacterium tuberculosis from patients smear-negative for acid-fast bacilli. Lancet. 1999;353:444–449.
   PubMed Web of Science ®Google Scholar
• Hernandez-Garduno E, Cook V, Kunimoto D, Elwood RK, Black WA, FitzGerald JM. Transmission of tuberculosis from smear negative patients: a molecular epidemiology study. Thorax. 2004;59:286–290.
   Web of Science ®Google Scholar
• Somoskovi A, Kodmon C, Lantos A, et al. Comparison of recoveries of mycobacterium tuberculosis using the automated BACTEC MGIT 960 system, the BACTEC 460 TB system, and Lowenstein–Jensen medium. J Clin Microbiol. 2000;38:2395–2397.
   PubMed Web of Science ®Google Scholar
• Kuo SHS, Shi WY, Lin T, et al. Taiwan Tuberculosis Control Report 2009. 4th ed. Taipei, Taiwan (ROC): Department of Health, Centers for Disease Control; 2009.
   Google Scholar
• Wang JY, Lee LN, Lai HC, et al. Performance assessment of the Capilia TB assay and the BD ProbeTec ET system for rapid culture confirmation of Mycobacterium tuberculosis. Diagn Microbiol Infect Dis. 2007;59:395–399.
   PubMed Web of Science ®Google Scholar
• Soo PC, Horng YT, Hsueh PR, et al. Direct and simultaneous identification of Mycobacterium tuberculosis complex (MTBC) and Mycobacterium tuberculosis (MTB) by rapid multiplex nested PCR-ICT assay. J Microbiol Methods. 2006;66:440–448.
   Web of Science ®Google Scholar
• Scott LE, McCarthy K, Gous N, et al. Comparison of Xpert MTB/RIF with other nucleic acid technologies for diagnosing pulmonary tuberculosis in a high HIV prevalence setting: a prospective study. PLoS Med. 2011;8:e1001061.
   PubMed Web of Science ®Google Scholar
• Davis JL, Kawamura LM, Chaisson LH, et al. Impact of GeneXpert MTB/RIF on patients and tuberculosis programs in a low-burden setting. A hypothetical trial. Am J Respir Crit Care Med. 2014;189:1551–1559.
   Web of Science ®Google Scholar
• Richeldi L, Barnini S, Saltini C. Molecular diagnosis of tuberculosis. Eur Respir J Suppl. 1995;20:689s–700s.
   Google Scholar
• Lopez B, Aguilar D, Orozco H, et al. A marked difference in pathogenesis and immune response induced by different Mycobacterium tuberculosis genotypes. Clin Exp Immunol. 2003;133:30–37.
   PubMed Web of Science ®Google Scholar
• Wang SX, Sng LH, Tay L. Preliminary study on rapid identification of Mycobacterium tuberculosis complex isolates by the BD ProbeTec ET system. J Med Microbiol. 2004;53:57–59.
   Web of Science ®Google Scholar
• Wang JY, Lee LN, Hsu HL, Hsueh PR, Luh KT. Performance assessment of the DR. MTBC screen assay and the BD ProbeTec ET system for direct detection of Mycobacterium tuberculosis in respiratory specimens. J Clin Microbiol. 2006;44:716–719.
   Google Scholar
• Rose DN. Benefits of screening for latent Mycobacterium tuberculosis infection. Arch Intern Med. 2000;160:1513–1521.
   PubMedGoogle Scholar
• Horsburgh CR Jr. Priorities for the treatment of latent tuberculosis infection in the United States. N Engl J Med. 2004;350:2060–2067.
   PubMed Web of Science ®Google Scholar
• Diel R, Loddenkemper R, Meywald-Walter K, Niemann S, Nienhaus A. Predictive value of a whole blood IFN-gamma assay for the development of active tuberculosis disease after recent infection with Mycobacterium tuberculosis. Am J Respir Crit Care Med. 2008;177:1164–1170.
   Google Scholar
• Boussiotis VA, Tsai EY, Yunis EJ, et al. IL-10-producing T cells suppress immune responses in anergic tuberculosis patients. J Clin Invest. 2000;105:1317–1325.
   PubMed Web of Science ®Google Scholar
• Pai M, Riley LW, Colford JM Jr. Interferon-gamma assays in the immunodiagnosis of tuberculosis: a systematic review. Lancet Infect Dis. 2004;4:761–776.
   PubMed Web of Science ®Google Scholar
• Berthet FX, Rasmussen PB, Rosenkrands I, Andersen P, Gicquel B. A Mycobacterium tuberculosis operon encoding ESAT-6 and a novel low-molecular-mass culture filtrate protein (CFP-10). Microbiology. 1998;144 (Pt 11):3195–3203.
   PubMedGoogle Scholar
• Sorensen AL, Nagai S, Houen G, Andersen P, Andersen AB. Purification and characterization of a low-molecular-mass T-cell antigen secreted by Mycobacterium tuberculosis. Infect Immun. 1995;63:1710–1717.
   PubMed Web of Science ®Google Scholar
• Mahairas GG, Sabo PJ, Hickey MJ, Singh DC, Stover CK. Molecular analysis of genetic differences between Mycobacterium bovis BCG and virulent M. bovis. J Bacteriol. 1996;178:1274–1282.
   Google Scholar
• Mazurek GH, Jereb J, Vernon A, et al. Updated guidelines for using Interferon Gamma Release Assays to detect Mycobacterium tuberculosis infection – United States, 2010. MMWR Recomm Rep. 2010;59:1–25.
   Google Scholar
• Menzies D, Pai M, Comstock G. Meta-analysis: new tests for the diagnosis of latent tuberculosis infection: areas of uncertainty and recommendations for research. Ann Intern Med. 2007;146:340–354.
   PubMed Web of Science ®Google Scholar
• Ringshausen FC, Nienhaus A, Schablon A, Schlosser S, Schultze-Werninghaus G, Rohde G. Predictors of persistently positive Mycobacterium-tuberculosis-specific interferon-gamma responses in the serial testing of health care workers. BMC Infect Dis. 2010;10:220.
   PubMed Web of Science ®Google Scholar
• Dyrhol-Riise AM, Gran G, Wentzel-Larsen T, Blomberg B, Haanshuus CG, Morkve O. Diagnosis and follow-up of treatment of latent tuberculosis; the utility of the QuantiFERON-TB Gold In-tube assay in outpatients from a tuberculosis low-endemic country. BMC Infect Dis. 2010;10:57.
   PubMed Web of Science ®Google Scholar
• Shu CC, Wu VC, Yang FJ, et al. Dynamic changes in positive interferon-gamma release assay in a dialysis population: an observational cohort study. J Infect. 2013;67:529–535.
   Web of Science ®Google Scholar
• Metcalfe JZ, Cattamanchi A, McCulloch CE, Lew JD, Ha NP, Graviss EA. Test variability of the QuantiFERON-TB gold in-tube assay in clinical practice. Am J Respir Crit Care Med. 2013;187:206–211.
   PubMed Web of Science ®Google Scholar
• Fong KS, Tomford JW, Teixeira L, et al. Challenges of interferon-gamma release assay conversions in serial testing of health-care workers in a TB control program. Chest. 2012;142:55–62.
   PubMed Web of Science ®Google Scholar
• Niu WY, Wan YG, Li MY, Wu ZX, Zhang LG, Wang JX. The diagnostic value of serum procalcitonin, IL-10 and C-reactive protein in community acquired pneumonia and tuberculosis. Eur Rev Med Pharmacol Sci. 2013;17:3329–3333.
   Web of Science ®Google Scholar
• Kang YA, Kwon SY, Yoon HI, Lee JH, Lee CT. Role of C-reactive protein and procalcitonin in differentiation of tuberculosis from bacterial community acquired pneumonia. Korean J Intern Med. 2009;24:337–342.
   PubMedGoogle Scholar
• Walzl G, Ronacher K, Hanekom W, Scriba TJ, Zumla A. Immunological biomarkers of tuberculosis. Nat Rev Immunol. 2011;11:343–354.
   PubMed Web of Science ®Google Scholar
• Harries A. . What is the additional yield from repeated sputum examinations by microscopy and culture. In: Frieden TR, editor. Toman’s Tuberculosis Case Detection, Treatment and Monitoring. Geneva, Switzerland: World Health Organization; 2004:46–50.
   Google Scholar
• Yang WC, Hwang SJ. Incidence, prevalence and mortality trends of dialysis end-stage renal disease in Taiwan from 1990 to 2001: the impact of national health insurance. Nephrol Dial Transplant. 2008;23:3977–3982.
   PubMed Web of Science ®Google Scholar
• Pai M, Joshi R, Dogra S, et al. Serial testing of health care workers for tuberculosis using interferon-gamma assay. Am J Respir Crit Care Med. 2006;174:349–355.
   PubMed Web of Science ®Google Scholar
• Newberry WM, Sanford JP. Defective cellular immunity in renal failure: depression of reactivity of lymphocytes to phytohemagglutinin by renal failure serum. J Clin Invest. 1971;50:1262–1271.
   PubMed Web of Science ®Google Scholar
• Papay P, Eser A, Winkler S, et al. Predictors of indeterminate IFN-gamma release assay in screening for latent TB in inflammatory bowel diseases. Eur J Clin Invest. 2011;41:1071–1076.
   PubMed Web of Science ®Google Scholar
• Targeted tuberculin testing and treatment of latent tuberculosis infection. American Thoracic Society. MMWR Recomm Rep. 2000;49:1–51.
   Google Scholar
• Shu CC, Wu MF, Hsu CL, et al. Apoptosis-associated biomarkers in tuberculosis: promising for diagnosis and prognosis prediction. BMC Infect Dis. 2013;13:45.
   Web of Science ®Google Scholar
• Lange B, Vavra M, Kern WV, Wagner D. Indeterminate results of a tuberculosis-specific interferon-gamma release assay in immunocompromised patients. Eur Respir J. 2010;35:1179–1182.
   PubMed Web of Science ®Google Scholar
• Shu CC, Wang JT, Lee CH, Wang JY, Lee LN, Yu CJ. Predicting results of mycobacterial culture on sputum smear reversion after anti-tuberculous treatment: a case control study. BMC Infect Dis. 2010;10:48.
   Web of Science ®Google Scholar
• Pollock KM, Whitworth HS, Montamat-Sicotte DJ, et al. T-cell immunophenotyping distinguishes active from latent tuberculosis. J Infect Dis. 2013;208:952–968.
   PubMed Web of Science ®Google Scholar
• Harari A, Rozot V, Bellutti Enders F, et al. Dominant TNF-alpha+ Mycobacterium tuberculosis-specific CD4+ T cell responses discriminate between latent infection and active disease. Nat Med. 2011;17:372–376.
   Google Scholar
• Hur YG, Kang YA, Jang SH, et al. Adjunctive biomarkers for improving diagnosis of tuberculosis and monitoring therapeutic effects. J Infect. Epub November 5, 2014.
   Google Scholar
• Chegou NN, Heyckendorf J, Walzl G, Lange C, Ruhwald M. Beyond the IFN-gamma horizon: biomarkers for immunodiagnosis of infection with Mycobacterium tuberculosis. Eur Respir J. 2014;43:1472–1486.
   Google Scholar
• Sutherland JS, de Jong BC, Jeffries DJ, Adetifa IM, Ota MO. Production of TNF-alpha, IL-12(p40) and IL-17 can discriminate between active TB disease and latent infection in a West African cohort. PloS One. 2010;5:e12365.
   PubMed Web of Science ®Google Scholar
• Steingart KR, Flores LL, Dendukuri N, et al. Commercial serological tests for the diagnosis of active pulmonary and extrapulmonary tuberculosis: an updated systematic review and meta-analysis. PLoS Med. 2011;8:e1001062.
   PubMed Web of Science ®Google Scholar
• Habel JE, Bursey EH, Rho BS, et al. Structure of Rv1848 (UreA), the Mycobacterium tuberculosis urease gamma subunit. Acta Crystallogr Sect F Struct Biol Cryst Commun. 2010;66:781–786.
   Google Scholar
• Phillips M, Cataneo RN, Condos R, et al. Volatile biomarkers of pulmonary tuberculosis in the breath. Tuberculosis. 2007;87:44–52.
   PubMed Web of Science ®Google Scholar
• Cha D, Cheng D, Liu M, Zeng Z, Hu X, Guan W. Analysis of fatty acids in sputum from patients with pulmonary tuberculosis using gas chromatography-mass spectrometry preceded by solid-phase microextraction and post-derivatization on the fiber. J Chromatogr A. 2009;1216:1450–1457.
   PubMedGoogle Scholar
• Green C, Huggett JF, Talbot E, Mwaba P, Reither K, Zumla AI. Rapid diagnosis of tuberculosis through the detection of mycobacterial DNA in urine by nucleic acid amplification methods. Lancet Infect Dis. 2009;9:505–511.
   PubMed Web of Science ®Google Scholar
• Minion J, Leung E, Talbot E, Dheda K, Pai M, Menzies D. Diagnosing tuberculosis with urine lipoarabinomannan: systematic review and meta-analysis. Eur Respir J. 2011;38:1398–1405.
   PubMed Web of Science ®Google Scholar
• Gounder CR, Kufa T, Wada NI, et al. Diagnostic accuracy of a urine lipoarabinomannan enzyme-linked immunosorbent assay for screening ambulatory HIV-infected persons for tuberculosis. J Acquir Immune Defic Syndr. 2011;58:219–223.
   Web of Science ®Google Scholar
• Lawn SD, Edwards DJ, Kranzer K, Vogt M, Bekker LG, Wood R. Urine lipoarabinomannan assay for tuberculosis screening before antiretroviral therapy diagnostic yield and association with immune reconstitution disease. AIDS. 2009;23:1875–1880.
   PubMed Web of Science ®Google Scholar
• Lawn SD, Kerkhoff AD, Vogt M, Wood R. Diagnostic accuracy of a low-cost, urine antigen, point-of-care screening assay for HIV-associated pulmonary tuberculosis before antiretroviral therapy: a descriptive study. Lancet Infect Dis. 2012;12:201–209.
   PubMed Web of Science ®Google Scholar
• Sharma SK, Mohan A. Extrapulmonary tuberculosis. Indian J Med Res. 2004;120:316–353.
   PubMed Web of Science ®Google Scholar
• Luh KT, Chiang CY, Lee JJ, et al. Taiwan Guidelines for TB Diagnosis and Treatment. 4th ed. Taipei, Taiwan (ROC): Center for Disease Control, Executive Yuan; 2011.
   Google Scholar
• Light RW. Update on tuberculous pleural effusion. Respirology. 2010;15:451–458.
   PubMed Web of Science ®Google Scholar
• Gopi A, Madhavan SM, Sharma SK, Sahn SA. Diagnosis and treatment of tuberculous pleural effusion in 2006. Chest. 2007;131:880–889.
   PubMed Web of Science ®Google Scholar
• Ruan SY, Chuang YC, Wang JY, et al. Revisiting tuberculous pleurisy: pleural fluid characteristics and diagnostic yield of mycobacterial culture in an endemic area. Thorax. 2012;67:822–827.
   PubMed Web of Science ®Google Scholar
• Lin MT, Wang JY, Yu CJ, Lee LN, Yang PC. Mycobacterium tuberculosis and polymorphonuclear pleural effusion: incidence and clinical pointers. Respir Med. 2009;103:820–826.
   Web of Science ®Google Scholar
• Keng LT, Shu CC, Chen JY, et al. Evaluating pleural ADA, ADA2, IFN-gamma and IGRA for diagnosing tuberculous pleurisy. J Infect. 2013;67:294–302.
   PubMed Web of Science ®Google Scholar
• Liu YC, Shin-Jung Lee S, Chen YS, Tu HZ, Chen BC, Huang TS. Differential diagnosis of tuberculous and malignant pleurisy using pleural fluid adenosine deaminase and interferon gamma in Taiwan. J Microbiol Immunol Infect. 2011;44:88–94.
   PubMedGoogle Scholar
• Dheda K, Van-Zyl Smit RN, Sechi LA, et al. Clinical diagnostic utility of IP-10 and LAM antigen levels for the diagnosis of tuberculous pleural effusions in a high burden setting. PloS One. 2009;4:e4689.
   PubMed Web of Science ®Google Scholar
• Khan FY, Hamza M, Omran AH, et al. Diagnostic value of pleural fluid interferon-gamma and adenosine deaminase in patients with pleural tuberculosis in Qatar. Int J Gen Med. 2013;6:13–18.
   Google Scholar
• Garcia-Zamalloa A, Taboada-Gomez J. Diagnostic accuracy of adenosine deaminase and lymphocyte proportion in pleural fluid for tuberculous pleurisy in different prevalence scenarios. PloS One. 2012;7:e38729.
   PubMed Web of Science ®Google Scholar
• Budak F, Uzaslan EK, Cangur S, Goral G, Oral HB. Increased pleural soluble fas ligand (sFasL) levels in tuberculosis pleurisy and its relation with T-helper type 1 cytokines. Lung. 2008;186:337–343.
   Web of Science ®Google Scholar
• Wu SH, Li CT, Lin CH, Chu JJ, Cheng ML, Lin KH. Soluble Fas ligand is another good diagnostic marker for tuberculous pleurisy. Diagn Microbiol Infect Dis. 2010;68:395–400.
   Web of Science ®Google Scholar
• Lee SH, Lee EJ, Min KH, et al. Procalcitonin as a diagnostic marker in differentiating parapneumonic effusion from tuberculous pleurisy or malignant effusion. Clin Biochem. 2013;46:1484–1488.
   PubMed Web of Science ®Google Scholar
• Shu CC, Wang JY, Hsu CL, et al. Diagnostic role of inflammatory and anti-inflammatory cytokines and effector molecules of cytotoxic T lymphocytes in tuberculous pleural effusion. Respirology. 2015;20:147–154.
   PubMed Web of Science ®Google Scholar